Nimotop (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This inhibition reduces calcium entry into the cells, causing vasodilation of the brain’s blood vessels. The resulting increase in cerebral blood flow helps protect neural tissue from ischemia following a subarachnoid hemorrhage.

The dosage of Nimotop is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Health‑care professionals follow established guidelines and adjust the regimen as needed; patients should not alter the dose without medical advice.

The safety of Nimotop in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and use is generally reserved for situations where the potential benefit justifies any possible risk to the fetus or infant. Consultation with a specialist is recommended.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nimotop (nimodipine) is distinguished by its preferential action on cerebral vessels, whereas many other vasodilators affect systemic circulation more broadly. This selectivity makes it particularly effective for preventing vasospasm after subarachnoid hemorrhage, while other agents may be used for peripheral hypertension or angina.

Nimotop should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture. Keep the product away from direct sunlight and do not store in a bathroom or other humid environment. No refrigeration is required for this oral tablet.

Nimotop is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency are individualized, and patients should follow the dosing schedule provided by their health‑care professional to maintain consistent drug levels.

The most serious adverse events include severe hypotension, bradycardia, hepatic dysfunction, and rare allergic reactions such as rash or anaphylaxis. Patients should be monitored for signs of these conditions, and any sudden changes in blood pressure or heart rate should prompt immediate medical evaluation.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. It should also be avoided in individuals with severe hypotension or uncontrolled heart failure unless specifically directed by a specialist, as the drug’s vasodilatory effect may exacerbate these conditions.